Xu Y - Search Results

1

Emerging therapies in cancer metabolism.

Xiao Y, Yu TJ, Xu Y, Ding R, Wang YP, Jiang YZ, Shao ZM. Xiao Y, et al. Among authors: xu y. Cell Metab. 2023 Aug 8;35(8):1283-1303. doi: 10.1016/j.cmet.2023.07.006. Cell Metab. 2023. PMID: 37557070 Review.

2

Taxanes directly induce T cell cytotoxic extracellular vesicles to eradicate tumor cells.

Xu Y, Xiao Y, Shao ZM. Xu Y, et al. Cancer Cell. 2023 Jun 12;41(6):1011-1013. doi: 10.1016/j.ccell.2023.05.012. Cancer Cell. 2023. PMID: 37311412

3

Guanosine diphosphate-mannose suppresses homologous recombination repair and potentiates antitumor immunity in triple-negative breast cancer.

Ding JH, Xiao Y, Yang F, Song XQ, Xu Y, Ding XH, Ding R, Shao ZM, Di GH, Jiang YZ. Ding JH, et al. Among authors: xu y. Sci Transl Med. 2024 Jan 3;16(728):eadg7740. doi: 10.1126/scitranslmed.adg7740. Epub 2024 Jan 3. Sci Transl Med. 2024. PMID: 38170790

4

Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial.

Fan L, Wang ZH, Ma LX, Wu SY, Wu J, Yu KD, Sui XY, Xu Y, Liu XY, Chen L, Zhang WJ, Jin X, Xiao Q, Shui RH, Xiao Y, Wang H, Yang YS, Huang XY, Cao AY, Li JJ, Di GH, Liu GY, Yang WT, Hu X, Xia Y, Liang QN, Jiang YZ, Shao ZM. Fan L, et al. Among authors: xu y. Lancet Oncol. 2024 Feb;25(2):184-197. doi: 10.1016/S1470-2045(23)00579-X. Epub 2024 Jan 8. Lancet Oncol. 2024. PMID: 38211606 Clinical Trial.

5

Stanniocalcin 1 is a phagocytosis checkpoint driving tumor immune resistance.

Lin H, Kryczek I, Li S, Green MD, Ali A, Hamasha R, Wei S, Vatan L, Szeliga W, Grove S, Li X, Li J, Wang W, Yan Y, Choi JE, Li G, Bian Y, Xu Y, Zhou J, Yu J, Xia H, Wang W, Alva A, Chinnaiyan AM, Cieslik M, Zou W. Lin H, et al. Among authors: xu y. Cancer Cell. 2021 Apr 12;39(4):480-493.e6. doi: 10.1016/j.ccell.2020.12.023. Epub 2021 Jan 28. Cancer Cell. 2021. PMID: 33513345 Free PMC article.

6

[Consideration of immune checkpoint inhibitors in cancer therapy].

Xu YY. Xu YY. Zhonghua Zhong Liu Za Zhi. 2016 Feb;38(2):156-9. doi: 10.3760/cma.j.issn.0253-3766.2016.02.015. Zhonghua Zhong Liu Za Zhi. 2016. PMID: 26899338 Chinese.

7

DFNA5 regulates immune cells infiltration and exhaustion.

Hu J, Pei W, Jiang M, Huang Y, Dong F, Jiang Z, Xu Y, Li Z. Hu J, et al. Among authors: xu y. Cancer Cell Int. 2022 Mar 5;22(1):107. doi: 10.1186/s12935-022-02487-0. Cancer Cell Int. 2022. PMID: 35248047 Free PMC article.

8

SENP5 promotes homologous recombination-mediated DNA damage repair in colorectal cancer cells through H2AZ deSUMOylation.

Liu T, Wang H, Chen Y, Wan Z, Du Z, Shen H, Yu Y, Ma S, Xu Y, Li Z, Yu N, Zhang F, Cao K, Cai J, Zhang W, Gao F, Yang Y. Liu T, et al. Among authors: xu y. J Exp Clin Cancer Res. 2023 Sep 8;42(1):234. doi: 10.1186/s13046-023-02789-9. J Exp Clin Cancer Res. 2023. PMID: 37684630 Free PMC article.

9

CC-115 Mediates GSDME-Dependent Pyroptosis in Lung Adenocarcinoma Through the Akt/Bax Pathway.

Zhang T, Liu MQ, Xie GS, Wu DM, Luo PW, Liu T, Deng SH, Wang YY, He S, Zhou Y, Zhou J, Xu Y. Zhang T, et al. Among authors: xu y. J Cancer. 2023 May 15;14(8):1350-1361. doi: 10.7150/jca.83175. eCollection 2023. J Cancer. 2023. PMID: 37283803 Free PMC article.

10

Assessing the role of programmed cell death signatures and related gene TOP2A in progression and prognostic prediction of clear cell renal cell carcinoma.

Wang Q, Liu J, Li R, Wang S, Xu Y, Wang Y, Zhang H, Zhou Y, Zhang X, Chen X, Zhuang W, Lin Y. Wang Q, et al. Among authors: xu y. Cancer Cell Int. 2024 May 10;24(1):164. doi: 10.1186/s12935-024-03346-w. Cancer Cell Int. 2024. PMID: 38730293

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

67,214 results

Search Page